ACCP - Store - I Can't Drive 55! A Review of New Therapeutic Agents and Recommendations for the Management of Lipids

I Can't Drive 55! A Review of New Therapeutic Agents and Recommendations for the Management of Lipids

Format to Purchase:

Member Price:
$24.95

Nonmember Price:
$49.95

Since the publication of the 2018 guidelines for the management of blood cholesterol, the development of new recommendations and the availability of new therapeutic agents have impacted the management of dyslipidemia. The first session of this program will review current therapy recommendations according to the most recent guidelines, including a review of the evidence suggesting that decreased low-density lipoprotein cholesterol (LDL-C) levels should be targeted for patients at increased risk of cardiovascular events. It will also discuss evidence supporting the use of novel, non-statin therapies and their place in therapy. The second portion of the program will involve a pro-con debate that will review the application of new and existing medications that may have a role in reaching lower LDL-C targets to a series of patient cases.

Release Date: November 12, 2025

ACPE Deadline: October 21, 2028

Publication Year: 2025
Format: Recorded Lecture
Technical Requirements:

To access this on-demand content, you will need broadband Internet access, an updated Internet browser, and speakers or headphones for audio.

MORE PRODUCTS IN THIS SERIES

I Can't Drive 55! A Review of New Therapeutic Agents and Recommendations for the Management of Lipids

A Moving Target: New Guidelines, New Goals and Novel Agents to Get Us There
The Great Debate: Selecting Lipid-Lowering Therapy After Maximally Tolerated Statins (Pro)
The Great Debate: Selecting Lipid-Lowering Therapy After Maximally Tolerated Statins (Con)

Faculty

	Bruce A. Warden, Pharm.D., CLS, FNLA, FASPC, BCPS Clinical Pharmacist General Cardiology Knight Cardiovascular Institute Oregon Health & Science University Portland, OR
	Kate Cabral, Pharm.D., FCCP, FACC, BCCP Associate Professor Albany College of Pharmacy & Health Sciences Director Metabolic Services Capital Cardiology Associates Albany, NY
	Kelsey E. Norman, Pharm.D., BCACP, BCCP Clinical Coordinator - Ambulatory Care & Scholarship & PGY2 Ambulatory Care Residency Program Director Boston Medical Center Boston, MA

The American College of Clinical Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Target Audience: Pharmacists

I Can't Drive 55! A Review of New Therapeutic Agents and Recommendations for the Management of Lipids Activity Number: 0217-0000-25-117-H01-P Contact Hour(s): 1.50 Activity Type: Application BasedLearning Objectives Summarize updated treatment pathways for lipid management according to the most recent guidelines. Differentiate recommendations for targeting low-density lipoprotein cholesterol (LDL-C) levels for patients at risk for cardiovascular events. Evaluate the role of newer non-statin agents in lipid management. Debate the optimal approach to cardiovascular risk reduction using lipid-lowering therapy.

The American College of Clinical Pharmacy does not solicit or accept external commercial/financial support for its continuing pharmacy education activities. No commercial/financial support has been solicited or accepted for this activity.

I Can't Drive 55! A Review of New Therapeutic Agents and Recommendations for the Management of Lipids

Contents

I Can't Drive 55! A Review of New Therapeutic Agents and Recommendations for the Management of Lipids

I Can't Drive 55! A Review of New Therapeutic Agents and Recommendations for the Management of Lipids

Faculty

CPE Credit

Contents

I Can't Drive 55! A Review of New Therapeutic Agents and Recommendations for the Management of Lipids

Commercial Support

Cookies